

## Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis and Reflex to Titer and Neuronal Immunoblot

| Patient:                                  | Client:   | ARUP Test Code: 2007967   |  |
|---|---|---|--|
| Patient Identifiers:  Visit Number (FIN): | Physician:  | Collection Date: 02/11/2022<br>Received in lab: 02/13/2022<br>Completion Date: 02/17/2022   |  |
| Albumin                                   | 3.94 g/dL   | (Ref Interval: 3.75-5.01)   |  |
| Alpha 1 Globulin                          | 0.37 g/dL   | (Ref Interval: 0.19-0.46)   |  |
| Alpha 2 Globulin                          | 0.68 g/d∟   | (Ref Interval: 0.48-1.05)   |  |
| Beta Globulin                             | 1.07 g/dL   | (Ref Interval: 0.48-1.10)   |  |
| Gamma                                     | 1.04 g/dL   | (Ref Interval: 0.62-1.51)   |  |
| Immunofixation                            | IFE Done  |   |  |
| Immunoglobulin A                          | 329 mg/dL REFERENCE INTERVAL: Access complete set intervals for this t (aruplab.com). | (Ref Interval: 68-408) Immunoglobulin A of age- and/or gender-specific reference est in the ARUP Laboratory Test Directory  |  |
| Immunoglobulin G                          | 923 mg/dL REFERENCE INTERVAL: Access complete set intervals for this t (aruplab.com). | (Ref Interval: 768-1632)<br>Immunoglobulin G<br>of age- and/or gender-specific reference<br>est in the ARUP Laboratory Test Directory                                 |  |
| Immunoglobulin M                          | 250 mg/dL REFERENCE INTERVAL: Access complete set intervals for this t (aruplab.com). | (Ref Interval: 35-263) Immunoglobulin M of age- and/or gender-specific reference est in the ARUP Laboratory Test Directory  |  |
| Total Protein, Serum                      | 7.1 g/dL  | (Ref Interval: 6.3-8.2)   |  |
| Asialo-GM1 Antibodies, IgG/IgM            | 10 IV   | (Ref Interval: 0-50)  |  |
| GM1 Antibodies, IgG/IgM                   | 15 IV   | (Ref Interval: 0-50)  |  |
| GD1a Antibodies, IgG/IgM                  | 10 IV   | (Ref Interval: 0-50)  |  |
| GD1b Antibodies, IgG/IgM                  | 8 IV  | (Ref Interval: 0-50)  |  |
| GQ1b Antibodies, IgG/IgM                  | 6 IV<br>INTERPRETIVE INFORMA<br>GD1a, GD1b, and GQ1b                                  | (Ref Interval: 0-50)<br>TION: Ganglioside (Asialo-GM1, GM1, GM2,<br>O) Antibodies, IgG/IgM  |  |
|   | 30-50 IV: Equivocal<br>51-100 IV: Positive  | 29 IV or less: Negative<br>30-50 IV: Equivocal<br>51-100 IV: Positive<br>101 IV or greater: Strong Positive   |  |
|   | neuropathies. Eleva   | Ganglioside antibodes are associated with diverse peripheral neuropathies. Elevated antibody levels to ganglioside-monosialic acid (GM1), and the neutral glycolipid, |  |
|   |   | Patient:  |  |









Patient: ARUP Accession: 22-042-133048

## Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis and Reflex to Titer and Neuronal Immunoblot

Patient Identifiers:

| Date of Birth: | Visit Number (FIN):

| Sex: | | Physician:

asialo GM1 are associated with motor or sensorimotor neuropathies, particularly multifocal motor neuropathy.

Anti-GM1 may occur as IgM (polyclonal or monoclonal) or IgG antibodies. These antibodies may also be found in patients with diverse connective tissue diseases as well as normal individuals. GD1a antibodies are associated with different individuals. GD1a antibodies are associated with different variants of Guillain-Barre syndrome (GBS) particularly acute motor axonal neuropathy while GD1b antibodies are predominantly found in sensory ataxic neuropathy syndrome. Anti-GQ1b antibodies are seen in more than 80 percent of patients with Miller-Fisher syndrome and may be elevated in GBS patients with ophthalmoplegia. The role of isolated anti-GM2 antibodies is unknown. These tests by themselves are not diagnostic and should be used in conjunction with other clinical parameters to confirm disease.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

SGPG Antibody, IgM

0.36 IV

(Ref Interval: 0.00-0.99)

INTERPRETIVE INFORMATION: SGPG Antibody. Igm

The majority of sulfate-3-glucuronyl paragloboside (SGPG) IgM-positive

sera will show reactivity against MAG. Patients who are SGPG IgM positive and MAG IgM negative may have multi-focal motor neuropathy

with conduction block.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

MAG Antibody, IgM Elisa

<1000 TU

(Ref Interval: 0-999)

INTERPRETIVE INFORMATION: MAG Antibody, Igm ELISA

An elevated IgM antibody concentration greater than 999 TU against myelin-associated glycoprotein (MAG) suggests active demyelination in peripheral neuropathy. A normal concentration (less than 999 TU) generally rules out an anti-MAG antibody-associated peripheral neuropathy.

TU=Titer Units

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

SPEP/IFE Interpretation

See Note

Normal SPEP pattern. IFE gel shows a normal pattern; no monoclonal proteins seen.

Purkinje Cell/Neuronal Nuclear IgG Scrn

None Detected

(Ref Interval: None Detected)

ANNA-1, ANNA-2, PCCA-1 or PCCA-Tr(DNER) antibodies not detected. No further testing will be performed.

INTERPRETIVE INFORMATION: Purkinje Cell/Neuronal Nuclear IgG Scrn

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or









Patient: ARUP Accession: 22-042-133048 Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis and Reflex to Titer and Neuronal Immunoblot

Patient: | Date of Birth: | Sex: | Physician: | Patient Identifiers: | Visit Number (FIN): | Visit Number

approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Only the Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis results are included in this enhanced report. If the reflex test is added, those results can be accessed via a patient report or electronic medical record system after reflex testing is completed. Reflex testing occurs when neuronal nuclear IgG (purkinje cell) IFA results are positive. A titer is added, and if that titer is positive, neuronal nuclear IgG (Hu, Ri, and Yo) testing is added.

Note: Electrophoresis image and Immunofixation (IFE) Gel image, as applicable, continue on following page.









Motor and Sensory Neuropathy Evaluation with Immunofixation Electrophoresis and Reflex to Titer and Neuronal Immunoblot









